{"id":573835,"date":"2022-12-30T00:00:00","date_gmt":"2022-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0007-2026-biopharma-human-immunodeficiency-virus-landscape-forecast-disease-landscape-forecast-pre-exposure\/"},"modified":"2026-03-31T10:35:26","modified_gmt":"2026-03-31T10:35:26","slug":"dlsfid0007-2026-biopharma-human-immunodeficiency-virus-landscape-forecast-disease-landscape-forecast-pre-exposure","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0007-2026-biopharma-human-immunodeficiency-virus-landscape-forecast-disease-landscape-forecast-pre-exposure\/","title":{"rendered":"Human Immunodeficiency Virus &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast: Pre-exposure Prophylaxis &#8211; G7"},"content":{"rendered":"<div>\n<p>Pre-exposure prophylaxis (<abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr>) is a key prevention strategy for ending the human immunodeficiency virus (<abbr title=\"human immunodeficiency virus\">HIV<\/abbr>) epidemic. The <abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u2019s approval of Gilead\u2019s Truvada in 2012 and Descovy in 2019 provided the first two <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> options for <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> prevention in individuals who are <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>-negative but at risk of sexually acquired <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>-1 infection. The <abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u2019s approval of ViiV\u2019s Apretude (cabotegravir) in December 2021 will provide an additional option and enable preferential prescribing to the <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr>-eligible population. In addition, many late-phase <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> therapies, such as Gilead\u2019s lenacapavir, are expected to offer less-frequent dosing, as well as improved safety, to become key differentiating attributes in <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> prevention. The <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> market will continue to grow owing to the launch of generic versions of Truvada, increasing initiatives by the government and companies to provide free <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> drugs, and growing awareness of <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> that will lead to an increase in the target population. In this report, we explore the clinical and commercial potential of approved and emerging <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> therapies.<\/p>\n<\/div>\n<div>\n<p><strong>Questions answered<\/strong><\/p>\n<\/div>\n<ul class=\"BulletListStyle1 SCXP49271269 BCX0 round-bullets\">\n<li>How large is the <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr>-eligible population in the United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, and Japan? How will the population change over the forecast period?<\/li>\n<li>What is the current market landscape for <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr>? How will <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> emerging therapies like lenacapavir compete with Apretude and other entrenched brands like Descovy and Truvada?<\/li>\n<li>What are the healthcare policies that will influence access and reimbursement of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> therapies, and how much of an impact will these strategies have?<\/li>\n<li>What are the most promising agents in the <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> pipeline, and how will they be differentiated from current therapies? What sales \/ uptake could emerging therapies secure during the forecast period?<\/li>\n<\/ul>\n<div>\n<p><strong>GEOGRAPHIES<\/strong><\/p>\n<p>United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>PRIMARY<\/strong><strong> <\/strong><strong>RESEARCH<\/strong><\/p>\n<div>\n<p>17 country-specific interviews with thought-leading infectious disease and internal medicine physicians<\/p>\n<\/div>\n<div>\n<p>Supported by survey data collected for this and other Clarivate research<\/p>\n<\/div>\n<p><strong>EPIDEMIOLOGY<\/strong><\/p>\n<p>Number of <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr>-eligible populations by country<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> <abbr title=\"pre-exposure prophylaxis\">PrEP<\/abbr> therapies through 2031, segmented by brands \/ generics<\/p>\n<p><strong>EMERGING <\/strong><strong>THERAPIES<\/strong><\/p>\n<p>Phase III \/ <abbr title=\"preregistered\">PR<\/abbr>: <span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"5\" data-last-change-time=\"1669990308002\" data-time=\"1669990308002\" data-userid=\"2868\" data-username=\"Archita\">1<\/span> drug; coverage of select early-phase products<\/p>\n<p>Marketed drugs: 3<\/p>\n<p><strong>Product description<\/strong><\/p>\n<\/div>\n<div>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<\/div>\n<div>\n<p><strong>Solution enhancement<\/strong><\/p>\n<\/div>\n<div>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-573835","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-human-immunodeficiency-virus","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573835\/revisions"}],"predecessor-version":[{"id":576135,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573835\/revisions\/576135"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}